Cytek Biosciences Inc
NASDAQ:CTKB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.9), the stock would be worth $5 (12% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | $4.46 |
0%
|
| 3-Year Average | 1.9 | $5 |
+12%
|
| 5-Year Average | 2.4 | $6.41 |
+44%
|
| Industry Average | 4.3 | $11.37 |
+155%
|
| Country Average | 2.5 | $6.68 |
+50%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
573.3m USD | 1.7 | -8.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
962.6B USD | 132.8 | 3 990.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 3.3 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 2.4 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.6B CNY | 3.7 | 15.5 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 3.9 | -122.9 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.7 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 11.5 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 4.3 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | -1 098 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Cytek Biosciences Inc
Glance View
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
